Novel Sulfide Releasing Agents for Ischemic Injury
用于缺血性损伤的新型硫化物释放剂
基本信息
- 批准号:8889814
- 负责人:
- 金额:$ 3.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-02-17 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute myocardial infarctionAddressAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApoptoticBiologicalBiological ModelsBiologyBiomedical ResearchCarbon MonoxideCardiacCationsCellsChemical AgentsChemistryChronicClinicalDataDendrimersDetectionDevelopmentDiseaseDown-RegulationDrug KineticsExhibitsFutureGenerationsGoalsHealthHeart failureHydrogen SulfideHypoxiaIn VitroInfarctionInjuryInvestigationLeadLeft Ventricular FunctionLifeLightMeasuresMetabolismMethodsMitochondriaModelingModificationMonitorMusMuscle CellsMyocardial IschemiaMyocardiumNitric OxideOxidative StressOxygen ConsumptionPharmacologyPhysiologyProblem SolvingProductionReperfusion InjuryReperfusion TherapyResearchResearch PersonnelRespirationSeriesSignaling MoleculeSolidStructure-Activity RelationshipSulfhydryl CompoundsSulfidesTestingTherapeuticTimeVasodilationbasecytotoxicitydesigndithioldrug developmentimprovedin vivoin vivo Modelnovelphosphorodithioic acidprotective effectresearch studytool
项目摘要
DESCRIPTION (provided by applicant): Hydrogen sulfide (H2S) is a newly recognized signaling molecule with very potent cytoprotective actions. The fields of H2S physiology and pharmacology have been rapidly growing in recent years, but a number of fundamental issues must be addressed to advance our understanding of the biology and clinical potential of H2S in the future. It is important to study the chemistry and pharmacology of exogenous H2S, to be aware of the limitations associated with the choice of chemical agents used to generate H2S in vitro and in vivo. In this regard, synthetic H2S-releasing agents (i.e. H2S donors) are important research tools and potentially very valuable therapeutic candidates for drug development. However, currently available H2S donors are very limited in terms of research use or clinical development since those compounds are very short-lived and the timing and amount of H2S release is largely uncontrollable. To solve these problems, we have recently developed four types of new H2S donors based on N-mercapto, perthiol, gem-dithiol, and phosphorodithioate templates. H2S generations from these donors can be controlled by different mechanisms and the rates of H2S generation can be regulated upon structural modifications. We also found that the administration of H2S donors at the time of reperfusion significantly decreased infarct size and preserved left ventricular function in an in vivo murine model of myocardial ischemia/reperfusion injury. In this project, we plan to develop a toolbox of long-lasting and controllable H2S releasing agents and apply them to explore the pharmacology of H2S under pathological disease states in in vitro and in vivo model systems. Three Specific Aims will be pursued: 1) to design, synthesize, and evaluate controllable H2S donors, 2) to screen the activities of synthetic H2S donors under in vitro conditions; and 3) to examine the cardioprotective actions of donors in acute myocardial ischemia/reperfusion (MI/R) injury and chronic heart failure. We believe that the proposed research will expand our understanding of the chemistry/pharmacology of H2S and provide valuable tools and information to facilitate H2S biomedical research.
描述(由申请人提供):硫化氢(H2S)是一种新发现的信号分子,具有非常强的细胞保护作用。近年来,H2S生理学和药理学领域迅速发展,但必须解决一些基本问题,以促进我们对未来H2S生物学和临床潜力的理解。重要的是要研究外源性H2S的化学和药理学,了解与用于在体外和体内产生H2S的化学试剂的选择相关的限制。在这方面,合成的H2S释放剂(即H2S供体)是重要的研究工具和潜在的非常有价值的治疗药物开发的候选人。然而,目前可用的H2S供体在研究用途或临床开发方面非常有限,因为这些化合物非常短,并且H2S释放的时间和量在很大程度上是不可控的。为了解决这些问题,我们最近开发了四种类型的新的H2S供体基于N-巯基,过硫醇,偕二硫醇,和二硫代磷酸酯模板。来自这些供体的H2S生成可以通过不同的机制来控制,并且H2S生成的速率可以在结构修饰后进行调节。我们还发现,在心肌缺血/再灌注损伤的体内小鼠模型中,在再灌注时给予H2S供体显著降低了梗死面积并保留了左心室功能。在本项目中,我们计划开发一种长效和可控的H2S释放剂工具箱,并将其应用于体外和体内模型系统中病理疾病状态下H2S的药理学研究。本研究的目的有三:1)设计、合成和评价可控H2S供体; 2)在体外条件下筛选合成H2S供体的活性; 3)检测供体在急性心肌缺血/再灌注(MI/R)损伤和慢性心力衰竭中的心脏保护作用。我们相信,拟议的研究将扩大我们的化学/药理学的H2S的理解,并提供有价值的工具和信息,以促进H2S的生物医学研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID JOSEPH LEFER其他文献
DAVID JOSEPH LEFER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID JOSEPH LEFER', 18)}}的其他基金
Endogenous Hydrogen Sulfide Enzymes in Heart Failure
心力衰竭中的内源性硫化氢酶
- 批准号:
10077584 - 财政年份:2019
- 资助金额:
$ 3.11万 - 项目类别:
Novel Mitochondrial DNA Repair Enzyme for Heart Failure
治疗心力衰竭的新型线粒体 DNA 修复酶
- 批准号:
9408031 - 财政年份:2017
- 资助金额:
$ 3.11万 - 项目类别:
Novel antifibrotic small molecules for the treatment of heart failure
用于治疗心力衰竭的新型抗纤维化小分子
- 批准号:
9142025 - 财政年份:2016
- 资助金额:
$ 3.11万 - 项目类别:
Novel Sulfide Releasing Agents for Ischemic Injury
用于缺血性损伤的新型硫化物释放剂
- 批准号:
8629076 - 财政年份:2014
- 资助金额:
$ 3.11万 - 项目类别:
相似海外基金
Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
- 批准号:
MR/Y009770/1 - 财政年份:2023
- 资助金额:
$ 3.11万 - 项目类别:
Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
- 批准号:
23K15160 - 财政年份:2023
- 资助金额:
$ 3.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
- 批准号:
10709134 - 财政年份:2023
- 资助金额:
$ 3.11万 - 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
- 批准号:
10603548 - 财政年份:2023
- 资助金额:
$ 3.11万 - 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10576349 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
- 批准号:
22K09185 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
- 批准号:
22K08135 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
- 批准号:
468573 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Operating Grants
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10339915 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
- 批准号:
nhmrc : 2005797 - 财政年份:2021
- 资助金额:
$ 3.11万 - 项目类别:
Partnership Projects